Maze Therapeutics, Inc. (NASDAQ:MAZE – Get Free Report) insider Atul Dandekar sold 7,500 shares of the business’s stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $27.58, for a total value of $206,850.00. Following the transaction, the insider owned 26,250 shares of the company’s stock, valued at approximately $723,975. The trade was a 22.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Atul Dandekar also recently made the following trade(s):
- On Wednesday, July 29th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The shares were sold at an average price of $27.34, for a total value of $205,050.00.
- On Monday, June 29th, Atul Dandekar sold 7,500 shares of Maze Therapeutics stock. The shares were sold at an average price of $28.02, for a total value of $210,150.00.
Maze Therapeutics Price Performance
Shares of MAZE traded down $0.87 during trading hours on Monday, reaching $26.57. 493,470 shares of the company’s stock traded hands, compared to its average volume of 643,897. Maze Therapeutics, Inc. has a 12 month low of $13.89 and a 12 month high of $53.65. The company has a current ratio of 18.31, a quick ratio of 18.31 and a debt-to-equity ratio of 0.09. The stock has a market cap of $1.48 billion, a PE ratio of -10.54 and a beta of 2.22. The firm’s 50 day simple moving average is $28.74 and its 200-day simple moving average is $31.79.
Institutional Investors Weigh In On Maze Therapeutics
A number of hedge funds have recently made changes to their positions in MAZE. California State Teachers Retirement System boosted its stake in shares of Maze Therapeutics by 54,096.5% in the 2nd quarter. California State Teachers Retirement System now owns 777,720 shares of the company’s stock valued at $23,207,000 after purchasing an additional 776,285 shares in the last quarter. Frazier Life Sciences Management L.P. lifted its stake in Maze Therapeutics by 10.2% in the second quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company’s stock worth $150,182,000 after purchasing an additional 465,641 shares during the last quarter. AXQ Capital LP lifted its stake in Maze Therapeutics by 114.1% in the second quarter. AXQ Capital LP now owns 15,193 shares of the company’s stock worth $453,000 after purchasing an additional 8,098 shares during the last quarter. Braidwell LP purchased a new stake in Maze Therapeutics during the second quarter valued at about $34,019,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Maze Therapeutics by 4,054.3% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 17,739 shares of the company’s stock valued at $529,000 after buying an additional 17,312 shares during the period.
Wall Street Analyst Weigh In
A number of equities analysts have recently commented on the stock. TD Cowen raised shares of Maze Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. Wall Street Zen cut Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, BTIG Research restated a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a research report on Wednesday, August 12th. Three investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $66.00.
View Our Latest Stock Analysis on MAZE
About Maze Therapeutics
Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.
Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.
Featured Articles
- Five stocks we like better than Maze Therapeutics
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Receive News & Ratings for Maze Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maze Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
